Sponsors
Blog
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?25 May 2011
White Papers
Focus Area: Manufacturing
The Small Company That Grew
Once a minor force in the world pharmaceutical market, Nycomed became a major player following its acquisition of Altana Pharma in 2006. CEO Håkan Björklund tells Marie Shields how the company is positioned to meet the challenges of its extraordinary growth.
Blinding into capsules: a specialist job
By Creapharm. Most clinical studies are blind studies and therefore require that the patient or the physician (blind study) or both (double blind study) cannot identify the treatment drug, be it the tested active drug or the placebo or the comparator drug.
Geodis targets new pharma markets
By Geodis Wilson. Forwarder identifies rich pickings to be made from growing demand in China and India.
Managing variation, uncertainty and risk
By JMP. The FDA believes we badly need “a maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight”. What could or should we each do to help the desired state more likely?
Offering excellence in contract manufacturing services
Reliability, responsiveness and a strong focus on results: these virtues form the base for Nycomed’s policy of becoming the preferred pharmaceutical company. Nycomed has established itself among the world’s 25 largest pharmaceutical companies and is the 15th largest provider of over-the-counter medicines.
Source: www.ngpharma.eu.com© 2012 GDS Publishing Ltd. All rights reserved.